These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1478357)

  • 1. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 2. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic stability: an issue of product quality.
    Burns N
    Biologicals; 1993 Jun; 21(2):145-6. PubMed ID: 8297594
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic stability and product consistency of rDNA derived biologicals.
    Lambert KJ
    Biologicals; 1993 Jun; 21(2):151. PubMed ID: 8297596
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells.
    Bebbington CR; Lambert K
    Dev Biol Stand; 1994; 83():183-4. PubMed ID: 7883094
    [No Abstract]   [Full Text] [Related]  

  • 6. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 7. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM
    Dev Biol Stand; 1992; 76():299-300. PubMed ID: 1478347
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic stability and recombinant product consistency.
    Burstyn D; Copmann T; Dinowitz M; Garnick R; Losikoff A; Lubiniecki A; Wiebe M
    Biologicals; 1993 Jun; 21(2):147-9. PubMed ID: 8297595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioprocess factors affecting glycoprotein oligosaccharide structure.
    Goochee CF
    Dev Biol Stand; 1992; 76():95-104. PubMed ID: 1478360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 11. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 13. Gene expression--glycosylation.
    Parekh RB
    Biologicals; 1994 Jun; 22(2):113-9. PubMed ID: 7917227
    [No Abstract]   [Full Text] [Related]  

  • 14. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 15. Ensuring the consistency of rDNA-derived biologicals: the contribution of gene sequencing.
    Griffiths E
    Dev Biol Stand; 1994; 83():179-82. PubMed ID: 7883093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to the issues: recently developed methods for characterizing cell lines.
    Kozak RW
    Dev Biol Stand; 1992; 76():21-4. PubMed ID: 1478337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical devices of human origin.
    Williams D
    Med Device Technol; 2001 Apr; 12(3):8, 10-1. PubMed ID: 11547687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 20. Getting the glycosylation right: implications for the biotechnology industry.
    Jenkins N; Parekh RB; James DC
    Nat Biotechnol; 1996 Aug; 14(8):975-81. PubMed ID: 9631034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.